MedTrace Logo

Open Label Trial of Immunotherapy for Advanced Liver Cancer

NCT02256514 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2019-08-30

No results posted yet for this study

Summary

The purpose of this study is to evaluate daily dosing of oral immunotherapy hepcortespenlisimut-L (V5) in patients with advanced stage of HCC not amenable to surgical intervention or with recurrent tumor after surgery.

Conditions

Interventions

BIOLOGICAL

Daily oral dose of hepcortespenlisimut-L

Oral therapeutic vaccine, hepcortespenlisimut-L (V5) to be given once-per-day with monthly check-up

Sponsors & Collaborators

  • Immunitor Inc.

    collaborator INDUSTRY

  • Immunitor LLC

    lead INDUSTRY

Principal Investigators

  • Aldar Bourinbaiar, MD/PhD · Immunitor LLC

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-09-30
Primary Completion
2019-09-30
Completion
2019-12-31

Countries

  • Mongolia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02256514 on ClinicalTrials.gov